A-A-51399A
19 September 1986
SUPERSEDING
A-A-0051399 (DM)
7 April 1986
COMMERCIAL ITEM DESCRIPTION
THEOPHYLLINE CAPSULES, MODIFIED
The General Services Administration has authorized the use of this Commercial Item Description.
Salient Characteristics:
Shall be sustained-release, dye free Theophylline Capsules.
For Strength 1, shall contain 50 mg of anhydrous theophylline per capsule, within the applicable assay limits.
For Strength 2, shall contain 75 mg of anhydrous theophylline per capsule, within the applicable assay limits.
For Strength 3, shall contain 200 mg of anhydrous theophylline per capsule, within the applicable assay limits.
For Strength 4, shall contain 125 mg of anhydrous theophylline per capsule, within the applicable assay limits.
The sustained-release capsules must be considered by the FDA to be therapeutically equivalent with Theophylline Capsules by Key Pharmaceuticals at the same dosage and administration schedule.
Workmanship. Capsules shall be free from defects which detract from their appearance or impair their serviceability.
Unit. Bottle (BT). One bottle containing 100 capsules, as specified, constitutes one unit.
DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business